Current Report Filing (8-k)
July 21 2022 - 07:32AM
Edgar (US Regulatory)
false 0001813814 0001813814 2022-07-21
2022-07-21
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 21, 2022
MIND MEDICINE (MINDMED) INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
British Columbia, Canada |
|
001-40360 |
|
98-1582438 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.)
|
|
|
|
One World Trade Center, Suite
8500 |
|
|
New York, New York |
|
10007 |
(Address of Principal Executive
Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (650)
208-2454
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Shares |
|
MNMD |
|
The Nasdaq Stock Market
LLC |
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this
chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01 |
Regulation FD Disclosure.
|
On July 21, 2022, Mind Medicine (MindMed), Inc. (the “Company”)
posted a corporate presentation on the Company’s website, which the
Company may use from time to time in conversations with investors,
analysts or other third parties.
The information responsive to Item 7.01 of this Form 8-K, including Exhibit 99.1, shall not
be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise
subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such a filing and as set forth below
in Item 8.01 of this Current Report on Form 8-K.
As disclosed above, on July 21, 2022 the Company updated their
corporate deck, which is attached as Exhibit 99.1 hereto. The
information on slide 9 of Exhibit 99.1 is incorporated by reference
herein.
Item 9.01 |
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
MIND MEDICINE
(MINDMED) INC. |
|
|
|
|
Date: July 21, 2022 |
|
|
|
By: |
|
/s/ Cynthia Hu
|
|
|
|
|
Name: |
|
Cynthia Hu |
|
|
|
|
Title: |
|
Chief Legal Officer &
Secretary |
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From Feb 2023 to Mar 2023
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From Mar 2022 to Mar 2023